Takeda joins microbiome-focused biotech partner's $52.6M raise as it pursues more in-house cancer work
A high-profile collaboration with Takeda back in late 2018 bestowed upon Enterome some pharma validation and significant cash — $50 million upfront and another $15 million in R&D cost offset — to fund its microbiome platforms. It also represented the last of such licensing deals you’ll likely see from the French biotech in a while.
In the first financing since 2017, Enterome has topped up its reserves to $52.6 million (€46.3 million), most of which is going to the first-in-human studies of its cancer immunotherapy in recurrent glioblastoma and adrenal tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.